MedTrace Logo

Exploring the Tumor Micro-Environment with 68Ga-FAPi-46 PET/CT in Breast Cancer

NCT06790264 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-01-27

No results posted yet for this study

Summary

This study is a prospective, non-interventional, open-label study to evaluate the glucose metabolism and the expression of the imaging agent 68 Gallium-Fibroblast Activation Protein Inhibitor-46 (68Ga-FAPi-46) with PET imaging, in woman affected by Breast Cancer (BC) and referred to diagnostic imaging work-up prior to primary therapy.

Conditions

  • Breast Cancer Invasive
  • Node Positive Breast Cancer

Interventions

PROCEDURE

68Ga-FAPi-46 PET/CT

Study participants will undergo baseline assessments at enrollment with 68Ga-FAPi-46 PET/CT

Sponsors & Collaborators

  • European Institute of Oncology

    lead OTHER

Principal Investigators

  • Francesco Ceci, MD · European Istitute of Oncology

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-11-30
Completion
2025-11-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06790264 on ClinicalTrials.gov